XML 52 R37.htm IDEA: XBRL DOCUMENT
v3.22.0.1

REVENUES (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Revenue from Contract with Customer [Abstract] |
Contract with Customer, Contract Asset | The following table summarizes our contract assets:
as of December 31 (in millions) | 2021 | 2020
Contract manufacturing services | $ | 50 |  | $ | 47 |
Software sales | 45 |  | 40 |
Bundled equipment and consumable medical products contracts | 100 |  | 47 |
Contract assets | $ | 195 |  | $ | 134 |
The following table summarizes the classification of contract assets and contract liabilities as reported in the consolidated balance sheet:
as of December 31 (in millions) | 2021 | 2020
Prepaid expenses and other current assets | $ | 84 |  | $ | 70 |
Other non-current assets | 111 |  | 64 |
Contract assets | $ | 195 |  | $ | 134 |
Accrued expenses and other current liabilities | $ | 162 |  | $ | 32 |
Other non-current liabilities | 84 |  | 34 |
Contract liabilities | $ | 246 |  | $ | 66 |
Disaggregation of Revenue | The following tables disaggregate our net sales from contracts with customers by product category between the U.S. and international:
| 2021 |  | 2020 |  | 2019
years ended December 31 (in millions) | U.S. | International | Total |  | U.S. | International | Total |  | U.S. | International | Total
Renal Care 1 | $ | 890 |  | $ | 3,010 |  | $ | 3,900 |  |  | $ | 848 |  | $ | 2,909 |  | $ | 3,757 |  |  | $ | 791 |  | $ | 2,848 |  | $ | 3,639 |
Medication Delivery 2 | 1,859 |  | 1,021 |  | 2,880 |  |  | 1,738 |  | 953 |  | 2,691 |  |  | 1,762 |  | 977 |  | 2,739 |
Pharmaceuticals 3 | 753 |  | 1,538 |  | 2,291 |  |  | 849 |  | 1,249 |  | 2,098 |  |  | 904 |  | 1,215 |  | 2,119 |
Clinical Nutrition 4 | 343 |  | 621 |  | 964 |  |  | 330 |  | 580 |  | 910 |  |  | 308 |  | 552 |  | 860 |
Advanced Surgery 5 | 545 |  | 432 |  | 977 |  |  | 516 |  | 370 |  | 886 |  |  | 533 |  | 342 |  | 875 |
Acute Therapies 6 | 287 |  | 495 |  | 782 |  |  | 286 |  | 454 |  | 740 |  |  | 184 |  | 351 |  | 535 |
BioPharma Solutions 7 | 273 |  | 396 |  | 669 |  |  | 234 |  | 252 |  | 486 |  |  | 257 |  | 212 |  | 469 |
Patient Support Systems 8 | 86 |  | 29 |  | 115 |  |  | — |  | — |  | — |  |  | — |  | — |  | — |
Front Line Care 9 | 51 |  | 19 |  | 70 |  |  | — |  | — |  | — |  |  | — |  | — |  | — |
Surgical Solutions 10 | 12 |  | 15 |  | 27 |  |  | — |  | — |  | — |  |  | — |  | — |  | — |
Other 11 | 81 |  | 28 |  | 109 |  |  | 77 |  | 28 |  | 105 |  |  | 87 |  | 39 |  | 126 |
Total Baxter | $ | 5,180 |  | $ | 7,604 |  | $ | 12,784 |  |  | $ | 4,878 |  | $ | 6,795 |  | $ | 11,673 |  |  | $ | 4,826 |  | $ | 6,536 |  | $ | 11,362 |
1 Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services. 2 Medication Delivery includes sales of our IV therapies, infusion pumps, administration sets and drug reconstitution devices. 3 Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services. 4 Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products. 5 Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention. 6 Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU). 7 BioPharma Solutions includes sales of contracted services we provide to various pharmaceutical and biopharmaceutical companies. 8 Patient Support Systems includes sales of our connected care solutions: devices, software, communications and integration technologies. 9 Front Line Care includes sales of our integrated patient monitoring and diagnostic technologies to help diagnose, treat and manage a wide variety of illness and diseases, including respiratory therapy, cardiology, vision screening and physical assessment. 10 Surgical Solutions includes sales of our surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. 11 Other includes sales of miscellaneous product and service offerings.

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration